Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Necitumumab plus pembrolizumab in advanced NSCLC and SCCHN (Phase 1b, Japan)
jRCT2080223316Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of necitumumab and pembrolizumab in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), sponsored by Eli Lilly and Company. Started Sep 2016; status: completed.
02
Drugs
necitumumabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080223316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223316.